Shanghai Boyue Biotechnology Co. Ltd. has disclosed hepatocyte growth factor receptor (HGFR; MET) and tyrosine-protein kinase receptor UFO (AXL) inhibitors reported to be useful for the treatment of cancer.
Nextgen Bioscience Co. Ltd. has divulged ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors reported to be useful for the treatment of cancer, fibrosis, cardiovascular, inflammatory, respiratory, metabolic, eye and renal disorders, among others.<
Ohio State University has synthesized DNA topoisomerase II (bacterial) inhibitors reported to be useful for the treatment of Staphylococcus aureus infections.
Nanjing Tian Yin Jian Hua Pharma Tech Co. Ltd. has disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors acting as necroptosis inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, ulcerative colitis, multiple sclerosis, psoriasis, rheumatoid arthritis and Alzheimer’s disease, among others.
Holliston, Mass.-based Harvard Apparatus Regenerative Technology Inc. (HART) is seeking patent protection for synthetic structural support devices for use in esophageal tissue regeneration, in which the synthetic structural supports have been seeded with cells (e.g., mesenchymal stem cells) to form a cellular sheath on the supports’ outer surfaces.
Researchers at Oncopia Therapeutics Inc. (Proteovant Therapeutics Inc.) and University of Michigan have divulged conjugates comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to an estrogen receptor (ER) or zinc finger protein Helios (IKZF2) and/or zinc finger protein Aiolos (IKZF3) moiety through a linker.
RSS
